PRISYM ID makes new senior appointment to drive further grow...

PRISYM ID makes new senior appointment to drive further growth in clinical trials arena

Lundbeck gets cold feet, axes schizophrenia drug trial

Lundbeck has axed a phase 2 trial of a schizophrenia drug, saying that the study was unlikely to meet its efficacy target.

If our patients are diverse, why are clinical trials so whit...

Clinical decision support tools will help oncologists manage...

Making treatment decisions is a tough choice for oncologists: a therapy might save or significantly extend one patient’s life but not deliver the desired outcome for another patient.

ICMRA seeks international alignment on COVID-19 product asse...

COVID-19 drugs, vaccines and diagnostics that are developed and tested within new international guidelines can expect rapid assessment and authorisation.